CepTor Corporation

CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. An orphan disease is defined in the United States as a serious or life-threatening disease that affects less than 200,000 people and for which no definitive therapy currently exists. CepTor Corporation seeks to create an efficient orphan drug platform by taking advantage of the legislative, regulatory and commercial opportunities common to these rare diseases. CepTor's primary efforts are currently being focused on moving its lead product, MYODUR, into phase I/II clinical trials for Duchenne's muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis, retinal degeneration and epilepsy.

Contact Details: 200 International Circle, Suite 5100 Hunt Valley Maryland 21030-1350 United States of America Tel: 410-527-9998 Fax: 410-527-9867 Email: dfallon@ceptorcorp.com WWW: www.ceptorcorp.com/

Loading...

Recent Publications by CepTor Corporation:
Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. OBJECTIVE: Complications of atherosclerotic cardiovascular disease due to...	5th August, 2005	X-Ceptor Therapeutics Inc, San Diego, Calif 92121, USA.	Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):135-42. Epub 2004 Nov 11. DOI Direct Link
Regulation of complement C3 expression by the bile acid receptor FXR. The farnesoid X receptor (FXR; NR1H4) is an intracellular bile...	9th April, 2005	Department of Biology, X-Ceptor Therapeutics Inc., San Diego, California	J Biol Chem. 2005 Mar 4;280(9):7427-34. Epub 2004 Dec 7. DOI Direct Link
The flip side: Identifying small molecule regulators of nuclear receptors. Members of the nuclear hormone receptor superfamily function as...	8th January, 2005	X-Ceptor Therapeutics, 4756 Nexus Center Drive, Suite 200, San Diego, CA	Chem Biol. 2004 May;11(5):639-46. DOI Direct Link
Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. The estrogen-related receptor alpha (ERRalpha) is an orphan receptor...	24th December, 2004	Department of Medicinal Chemistry, X-Ceptor Therapeutics, Inc., 4757 Nexus	J Med Chem. 2004 Nov 4;47(23):5593-6. DOI Direct Link
Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator...	6th August, 2004	Department of Biology, X-Ceptor Therapeutics, Inc., San Diego, CA 92121,	Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7. Epub 2004 Jun 7. DOI Direct Link
→View more CepTor Corporation research publications.

CepTor Corporation Patents:
US Patent No.	Title
7115640	Heterocyclic modulators of nuclear receptors
6924311	Methods for affecting various diseases utilizing LXR compounds
6696473	Heterocyclic modulators of nuclear receptors

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 171 times since April 2007, the link to the organisation's website has been followed 25 times

Recent Search Terms used to find this page: CepTor corporation | .

Search for more companies in Hunt Valley

Search for more companies in Maryland

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for CepTor Corporation